Table 1 Baseline characteristics of patients
Cinepazide maleate (n = 466) | Placebo (n = 471) | Total (n = 937) | |
|---|---|---|---|
Age, years, mean (SD) | 60.3 (10.31) | 62.1 (9.65) | 61.2 (10.02) |
Sex, n (%) | |||
Male | 312 (67.0) | 309 (65.6) | 621 (66.3) |
Female | 154 (33.1) | 162 (34.4) | 316 (33.7) |
Ethnicity, n (%) | |||
Han | 443 (95.1) | 443 (94.1) | 886 (94.6) |
Others | 23 (4.9) | 28 (5.9) | 51 (5.4) |
BMI, kg/m2, mean (SD) | 24.4 (3.38) | 24.2 (3.30) | 24.3 (3.34) |
Onset of therapy, n (%) | |||
< 12 h | 24 (5.2) | 30 (6.4) | 54 (5.8) |
12–24 h | 122 (26.2) | 119 (25.3) | 241 (25.7) |
25–48 h | 316 (67.8) | 319 (67.7) | 635 (67.8) |
> 48 h | 4 (0.9) | 3 (0.6) | 7 (0.8) |
NIHSS score, median (Q1, Q3) | 8 (7, 10) | 8 (7, 10) | 8 (7, 10) |
mRS level, n (%) | |||
Level 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Level 1 | 0 (0.0) | 1 (0.2) | 1 (0.1) |
Level 2 | 7 (1.5) | 6 (1.3) | 13 (1.4) |
Level 3 | 136 (29.2) | 161 (34.2) | 297 (31.7) |
Level 4 | 303 (65.0) | 279 (59.2) | 582 (62.1) |
Level 5 | 20 (4.3) | 24 (5.1) | 44 (4.7) |
Prior history of stroke, n (%) | 141 (30.3) | 136 (28.9) | 277 (29.6) |
Comorbid disorders, n (%) | |||
Hypertension | 348 (74.7) | 343 (72.8) | 691 (73.8) |
Hyperlipidemia | 161 (34.6) | 156 (33.1) | 317 (33.8) |
Diabetes | 145 (31.1) | 160 (34.0) | 305 (32.6) |
Carotid atherosclerosis | 105 (22.5) | 128 (27.2) | 233 (24.9) |
Cerebral infarction | 110 (23.6) | 107 (22.7) | 217 (23.2) |
Cerebral artery stenosis | 90 (19.3) | 79 (16.8) | 169 (18.0) |
Cerebral arteriosclerosis | 83 (17.8) | 82 (17.4) | 165 (17.6) |
Carotid thrombosis | 82 (17.6) | 69 (14.7) | 151 (16.1) |
Arteriosclerosis | 65 (14.0) | 80 (17.0) | 145 (15.5) |
Hyperhomocysteinemia | 65 (14.0) | 71 (15.1) | 136 (14.5) |
Hepatic steatosis | 60 (12.9) | 63 (13.4) | 123 (13.1) |
Dyslipidemia | 46 (9.9) | 53 (11.3) | 99 (10.6) |
Coronary artery disease | 51 (10.9) | 43 (9.1) | 94 (10.0) |